Frontier Biotechnologies Inc. (SHA:688221)

China flag China · Delayed Price · Currency is CNY
21.10
-0.40 (-1.86%)
At close: Apr 29, 2026
Market Cap7.90B +115.3%
Revenue (ttm)392.19M +194.5%
Net Income3.46M
EPS0.01
Shares Out374.58M
PE Ratio2,282.80
Forward PE878.18
Dividendn/a
Ex-Dividend Daten/a
Volume31,980,900
Average Volume19,443,311
Open21.50
Previous Close21.50
Day's Range20.86 - 22.06
52-Week Range8.30 - 29.98
Beta1.06
RSI54.66
Earnings DateMar 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me... [Read more]

Sector Healthcare
Founded 2002
Employees 524
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688221
Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 123.39 million, a decrease of -4.70% compared to the previous year's 129.47 million. Losses were -268.05 million, 33.1% more than in 2024.

Financial Statements